

**CEREVEL THERAPEUTICS HOLDINGS, INC.**

222 Jacobs Street, Suite 200

Cambridge MA 02141

**VIA EDGAR**

November 18, 2021

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

**Re: Cerevel Therapeutics Holdings, Inc.**

**Acceleration Request for Registration Statement on Form S-3**

**Filed November 10, 2021**

**File No. 333-260945**

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cerevel Therapeutics Holdings, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to November 22, 2021, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable.

If you have any questions regarding this request, please contact Arthur McGivern of Goodwin Procter LLP at (617) 570 1971.

Sincerely,

**CEREVEL THERAPEUTICS HOLDINGS, INC.**

/s/ N. Anthony Coles

\_\_\_\_\_  
N. Anthony Coles

Chief Executive Officer

cc: Scott M. Akamine, *Cerevel Therapeutics Holdings, Inc.*

John Mei, *Cerevel Therapeutics Holdings, Inc.*

Stuart M. Cable, *Goodwin Procter LLP*

Arthur R. McGivern, *Goodwin Procter LLP*